Clinical spectrum of Lyme disease
Lyme disease (borreliosis) is one of the most common vector-borne diseases worldwide. Its incidence and geographic expansion has been steadily increasing in the last decades. Lyme disease is caused by Borrelia burgdorferi sensu lato, a heterogeneous group of which three genospecies have been systematically associated to Lyme disease: B. burgdorferi sensu stricto Borrelia afzelii and Borrelia garinii. Geographical distribution and clinical manifestations vary according to the species involved. Lyme disease clinical manifestations may be divided into three stages. Early localized stage is characterized by erythema migrans in the tick bite site. Early disseminated stage may present multiple erythema migrans lesions, borrelial lymphocytoma, lyme neuroborreliosis, carditis, or arthritis. The late disseminated stage manifests with acordermatitis chronica atrophicans, lyme arthritis, and neurological symptoms. Diagnosis is challenging due to the varied clinical manifestations it may present and usually involves a two-step serological approach. In the current review, we present a thorough revision of the clinical manifestations Lyme disease may present. Additionally, history, microbiology, diagnosis, post-treatment Lyme disease syndrome, treatment, and prognosis are discussed.
KeywordsLyme disease Borrelia burgdorferi Tick-borne diseases Ixodes Erythema migrans Lyme neuroborreliosis
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
Informed consent was obtained for iconographies.
- 2.Herrera Lorenzo O, Infante Ferrer J, Ramírez Reyes C, Lavastida Hernández H (2012) Enfermedad de Lyme: historia, microbiología, epizootiología y epidemiología. Rev Cubana Hig Epidemiol 50:231–244Google Scholar
- 18.Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, Mead PS (2016) Lyme borreliosis. Nat Rev Dis Primer 2:16090. https://doi.org/10.1038/nrdp.2016.90
- 21.Lenormand C, Jaulhac B, Debarbieux S, Dupin N, Granel-Brocard F, Adamski H et al (2016) Expanding the clinicopathological spectrum of late cutaneous Lyme borreliosis (acrodermatitis chronica atrophicans [ACA]): a prospective study of 20 culture- and/or polymerase chain reaction (PCR)-documented cases. J Am Acad Dermatol 74:685–692CrossRefGoogle Scholar
- 25.Gutierrez-Gomez C, Godinez-Hana AL, Garcia-Hernandez M, Suarez-Roa Mde L, Toussaint-Caire S, Vega-Memije E et al (2014) Lack of IgG antibody seropositivity to Borrelia burgdorferi in patients with Parry-Romberg syndrome and linear morphea en coup de sabre in Mexico. Int J Dermatol 53:947–951CrossRefGoogle Scholar
- 29.Scheffold N, Herkommer B, Kandolf R, May AE (2015) Lyme carditis--diagnosis, treatment and prognosis. Dtsch Arztebl Int 112:202–208Google Scholar
- 30.Marques AR (2015) Lyme neuroborreliosis. Continuum (Minneapolis, Minn). Neuroinfect Dis 21:1729–1744Google Scholar
- 34.Zajkowska J, Garkowski A, Moniuszko A, Czupryna P, Ptaszynska-Sarosiek I, Tarasow E et al (2015) Vasculitis and stroke due to Lyme neuroborreliosis - a review. Infect dis (London, England) 47:1–6Google Scholar
- 37.CDC (1995) MMWR Morbidity and mortality weekly report. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. https://www.cdc.gov/mmwr/preview/mmwrhtml/00042555.htm .Accesed 10 July 2018
- 41.Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS et al (2006) The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089–1134CrossRefGoogle Scholar